Skip to main content
. Author manuscript; available in PMC: 2011 Apr 1.
Published in final edited form as: Clin Infect Dis. 2010 Apr 1;50(7):1041–1052. doi: 10.1086/651118

Figure 1.

Figure 1

Subject randomization and disposition. Shown are numbers of subjects randomized, completing therapy, and included in the final analysis. LPV/r QD = lopinavir/ritonavir 800 mg/200mg once daily; LFU = lost to follow-up.